<DOC>
	<DOCNO>NCT02337829</DOCNO>
	<brief_summary>This study determine response acalabrutinib patient chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) .</brief_summary>
	<brief_title>Acalabrutinib Patients With Relapsed/Refractory Treatment naïve Deletion 17p CLL/SLL</brief_title>
	<detailed_description>To investigate safety efficacy acalabrutinib patient CLL/SLL relapsed/refractory disease treatment naive deletion 17p .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Men woman 18 year age old histologically confirm disease . Active disease define least one follow ( IWCLL consensus criterion ) : Weight loss ≥10 % within previous 6 month Extreme fatigue Fevers great 100.5ºF ≥2 week without evidence infection Night sweat one month without evidence infection Evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia Massive progressive splenomegaly Massive nod cluster progressive lymphadenopathy Progressive lymphocytosis increase &gt; 50 % 2 month period , anticipate double time le 6 month Compensated autoimmune hemolysis Relapsed/Refractory CLL/SLL treatment naïve patient Agreement use acceptable method contraception study 30 day last dose study drug sexually active able bear beget child . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty serial biopsy . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Radiotherapy , radioimmunotherapy , biological therapy , chemotherapy , investigational product last 4 week . Richter 's transformation . Autoimmune hemolytic anemia thrombocytopenia require steroid therapy . Impaired hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>Btk</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>ACP-196</keyword>
	<keyword>acalabrutinib</keyword>
</DOC>